Not actual patients.
Trial design
How was HYMPAVZI studied?
Trial overview
The efficacy and safety of HYMPAVZI was established in 116 hemophilia patients without inhibitors in the BASIS phase 3 study. The 18-month trial consisted of a 6-month observational period (when the patients were taking either on-demand factor replacement treatment or routine factor-based prophylactic treatment) followed by a 12-month active treatment period with HYMPAVZI.
Participants
adults and adolescent male participants ages 12+, with severe hemophilia A or B without inhibitors
routine factor-based prophylaxis participants
on-demand factor-based treatment participants